⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15586481 | 0.67 | — | — | |
| SCHEMBL19454252 | 0.65 | — | — | |
| SCHEMBL4574691 | 0.65 | — | — | |
| SCHEMBL2045505 | 0.63 | — | — | |
| SCHEMBL22903006 | 0.63 | — | — | |
| SCHEMBL2236284 | 0.63 | — | — | |
| SCHEMBL16131396 | 0.61 | — | — | |
| SCHEMBL330934 | 0.61 | — | — | |
| SCHEMBL332505 | 0.61 | — | — | |
| SCHEMBL29440891 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092731-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | ULTRAGENYX PHARMACEUTICAL INC. | 2024-03-21 | — | — | US | disclosed |
| US-11753369-B2 | Creatine prodrugs, compositions and methods of use thereof | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2023-09-12 | — | — | US | disclosed |
| CN-111417620-B | Creatine prodrugs, compositions thereof, and methods of use | 奥特吉尼克斯制药公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-115490751-A | Factor D inhibitors | 拜奥克里斯特制药公司 | 2022-12-20 | — | — | CN | disclosed |
| US-20220227703-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | ULTRAGENYX PHARMACEUTICAL INC. | 2022-07-21 | — | — | US | disclosed |
| CN-109121414-B | Benzopyrazole compounds and analogs thereof | 拜奥克里斯特制药公司 | 2022-07-05 | — | — | CN | disclosed |
| US-11332438-B2 | Creatine prodrugs, compositions and methods of use thereof | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2022-05-17 | — | — | US | disclosed |
| CN-112673015-A | CXCR 4-targeted diagnostic and therapeutic agents with reduced species selectivity | 慕尼黑工业大学 | 2021-04-16 | — | — | CN | disclosed |
| US-20210002211-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | ULTRAGENYX PHARMACEUTICAL INC. | 2021-01-07 | — | — | US | disclosed |
| CN-111868060-A | Dihydropyridophthalazinone derivative, preparation method and application thereof | 上海艾力斯医药科技股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| EP-3717453-A2 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | Ultragenyx Pharmaceutical Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
| CN-111417620-A | Creatine prodrugs, compositions thereof, and methods of use | 奥特吉尼克斯制药公司 | 2020-07-14 | — | — | CN | disclosed |
| EP-2490687-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-0971916-A1 | N-(ARGINYL)BENZENESULPHONAMIDE DERIVATIVES AND USE THEREOF AS ANTITHROMBOTIC AGENTS | SANOFI-SYNTHELABO (FR) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998042700-A1 | N-(ARGINYL)BENZENESULPHONAMIDE DERIVATIVES AND USE THEREOF AS ANTITHROMBOTIC AGENTS | SANOFI-SYNTHELABO (FR) | 1998-10-01 | — | — | WO | disclosed |